Atlas Trials

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Clinical trial NCT03323151 · COMPLETED

Trial details

NCT number
NCT03323151
Sponsor
PrECOG, LLC.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Mantle-Cell Lymphoma
Start date
2018-08-13
Primary completion
2022-09-22
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.